Excellent durability effect, well done to the PTX team.
The forthcoming phase 2 trial now has clearer data indicators towards its design target.
As a monotherapy, the PTX-100 is no less even more potent ( if you like), yes on a small population, than other gold standard of care. In this arena of deeply affected wellness, drugs like the PTX-100 offer a percentage of sufferers not only an alternate method of longevity, with fewer side effects, but further a longer survival duration. Hard to us for much more as a patient and from a potential drug in the making.
The rest is simply white noise, investor likes and dislikes (imo).
Again, well done to the PTX team.
Excellent durability effect, well done to the PTX team.The...
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
-0.002(4.17%) |
Mkt cap ! $37.04M | |||
| Open | High | Low | Value | Volume |
| 5.0¢ | 5.0¢ | 4.6¢ | $94.55K | 2.033M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7000 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 550000 | 2 |
View Market Depth
| Last trade - 15.36pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.8¢ |
Change
-0.002 ( 2.04 %) |
||||
| Open | High | Low | Volume | ||
| 4.7¢ | 4.8¢ | 4.5¢ | 409565 | ||
| Last updated 15.51pm 03/05/2024 ? | |||||
| PTX (ASX) Chart |